NCI seeks to develop clinical trial of MCED tests

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools. 

“Multi-cancer early detection tests are being developed by many laboratories, and the potential for this technology to benefit the cancer screening process is exciting, but, there is a lot that we do not know about either the benefits or harms of screening for cancer with this type of test,” Lori Minasian, deputy director of the NCI Division of Cancer Prevention, said to The Cancer Letter.

“An MCED assay is just the first step in the process of being diagnosed with cancer, and each assay works differently. We are looking for input from a variety of sources on studies to assess these assays more fully,” Minasian said.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Alice Tracey
Alice Tracey
Reporter

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.
When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
Alice Tracey
Alice Tracey
Reporter

Login